FDA Adverse Event Injury Summary report: N

HAKIM PROGRAMMABLE VALVE

MDR report key: 6289936 · Received January 31, 2017

Report

Report Number
1226348-2017-10076
Event Type
Injury
Date Received
January 31, 2017
Date of Event
January 10, 2017
Manufacturer
CODMAN & SHURTLEFF, INC. / MEDOS S.A.
Product Code
JXG
PMA / PMN Number
K974739
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
MEDICAL EQUIPMENT COMPANY TECHNICIAN/REPRESENTATIVE

Narratives

Additional Manufacturer Narrative · 1

(B)(4). UPON COMPLETION OF THE INVESTIGATION IT WAS NOTED THAT THE IMAGES WERE TAKEN OF THE ¿AS RECEIVED¿ VALVE. THE VALVE WAS VISUALLY INSPECTED: NO DEFECTS WERE NOTED. THE POSITION OF THE CAM WHEN VALVE WAS RECEIVED WAS 140MMH2O. THE VALVE WAS HYDRATED FOR 24 HOURS. THE VALVE WAS TESTED FOR PROGRAMMING WITH PROGRAMMER 82-3126 WITH SERIAL NUMBER (B)(4), THE VALVE PASSED THE TEST. THE VALVE WAS FLUSHED, THE VALVE PASSED THE TEST NO OCCLUSION WAS NOTED. THE VALVE WAS LEAK TESTED, ONLY LEAKED FROM THE NEEDLE HOLES IN THE NEEDLE CHAMBER. THE VALVE WAS REFLUX TESTED, THE VALVE PASSED THE TEST. THE VALVE WAS DRIED. THE VALVE WAS THEN PRESSURE TESTED, THE VALVE PASSED THE TEST. REVIEW OF THE HISTORY DEVICE RECORDS CONFIRMED THE VALVE PRODUCT CODE 82-3115, WITH LOT CLDBCH, CONFORMED TO THE SPECIFICATIONS WHEN RELEASED TO STOCK ON THE 29TH MARCH 2010. NO ROOT CAUSE COULD BE DETERMINED, AS THE PROBLEM REPORTED BY THE CUSTOMER COULD NOT BE DUPLICATED. BASED ON THE RESULTS OF THIS INVESTIGATION NO FURTHER ACTION IS REQUIRED. TRENDS WILL BE MONITORED FOR THIS AND SIMILAR COMPLAINTS. AT THE PRESENT TIME THIS COMPLAINT IS CLOSED.

Additional Manufacturer Narrative · 1

(B)(4). UPON COMPLETION OF THE INVESTIGATION A FOLLOW UP REPORT WILL BE FILED.

Description of Event or Problem · 1

SUSPECTED OVER DRAINAGE DESPITE 150 CM H2O.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
72853 HAKIM PROGRAMMABLE VALVE SHUNT, CENTRAL NERVOUS SYSTEM & COMPS JXG CODMAN & SHURTLEFF, INC. / MEDOS S.A. CLDBCH

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention